TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Island Pharmaceuticals Ltd ( (AU:ILA) ) has issued an announcement.
Island Pharmaceuticals Ltd announced a webinar to update stakeholders on its Galidesivir program, highlighting recent data from non-human primate studies and efforts to fast track approval for use against Marburg virus. This initiative reflects the company’s strategic focus on addressing high-priority viral threats and its commitment to advancing its clinical-stage antiviral molecule, potentially impacting its industry positioning and stakeholder interests.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on addressing urgent viral diseases, public health, or biosecurity threats. The company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir, targeting diseases such as dengue fever and other vector-borne diseases, as well as over 20 RNA viruses including Ebola, Marburg, MERS, Zika, and Yellow fever.
Average Trading Volume: 616,305
Technical Sentiment Signal: Buy
Current Market Cap: A$78.67M
For detailed information about ILA stock, go to TipRanks’ Stock Analysis page.